34.25
+0.88(+2.64%)
Currency In USD
| Previous Close | 33.37 |
| Open | 33.09 |
| Day High | 34.73 |
| Day Low | 32.37 |
| 52-Week High | 39.54 |
| 52-Week Low | 21.62 |
| Volume | 2.97M |
| Average Volume | 2.97M |
| Market Cap | 6.5B |
| PE | -9.62 |
| EPS | -3.56 |
| Moving Average 50 Days | 34.54 |
| Moving Average 200 Days | 30.09 |
| Change | 0.88 |
If you invested $1000 in BridgeBio Pharma, Inc. (BBIO) since IPO date, it would be worth $1,243.19 as of June 01, 2025 at a share price of $34.25. Whereas If you bought $1000 worth of BridgeBio Pharma, Inc. (BBIO) shares 5 years ago, it would be worth $1,185.94 as of June 01, 2025 at a share price of $34.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
GlobeNewswire Inc.
May 20, 2025 11:30 AM GMT
- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo - I
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
GlobeNewswire Inc.
May 19, 2025 4:33 PM GMT
- For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month 30, confirming the hypothesis that ever better levels of stabilization achieved by treatment w
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
GlobeNewswire Inc.
May 13, 2025 11:30 AM GMT
- ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction), establishing the mechani